首页 文献索引 SCI期刊 AI助手
期刊目录筛选

期刊名：Clinical advances in hematology & oncology

缩写：

ISSN：1543-0790

e-ISSN：

IF/分区：1.1/N/A

文章目录 更多期刊信息

共收录本刊相关文章索引2847条
Clinical Trial Case Reports Meta-Analysis RCT Review Systematic Review
Classical Article Case Reports Clinical Study Clinical Trial Clinical Trial Protocol Comment Comparative Study Editorial Guideline Letter Meta-Analysis Multicenter Study Observational Study Randomized Controlled Trial Review Systematic Review
Cabozantinib plus nivolumab as first-line therapy for advanced renal cell carcinoma with bone metastases: a clinical case report [0.03%]
Daniel J George Daniel J George
Clinical advances in hematology & oncology : H&O. 2026 May;24(3 Suppl 3):1-12. DOI: 2026
Updates in the management of small cell lung cancer [0.03%]
Jyoti Malhotra Jyoti Malhotra
Clinical advances in hematology & oncology : H&O. 2026 May;24(3):177-179. DOI: 2026
Periprocedural management of patients on antithrombotic therapy [0.03%]
Robert D McBane Robert D McBane
Clinical advances in hematology & oncology : H&O. 2026 May;24(3):173-176. DOI: 2026
How to implement DPYD genotyping into practice [0.03%]
Alan P Venook Alan P Venook
Clinical advances in hematology & oncology : H&O. 2026 May;24(3):170-172. DOI: 2026
Update on immune checkpoint inhibition for cervical cancer [0.03%]
Linda R Duska Linda R Duska
Clinical advances in hematology & oncology : H&O. 2026 May;24(3):167-169. DOI: 2026
The addition of PARP inhibition to androgen receptor pathway inhibition in metastatic hormone-sensitive prostate cancer [0.03%]
Gerhardt Attard Gerhardt Attard
Clinical advances in hematology & oncology : H&O. 2026 May;24(3):157-159. DOI: 2026
Hemophagocytic lymphohistiocytosis: new grading classification and targeted therapies [0.03%]
Edo Schaefer,Tishi Shah,Alissa Zhu et al. Edo Schaefer et al.
Hemophagocytic lymphohistiocytosis (HLH), both primary/familial HLH and secondary HLH, is associated with multiorgan dysfunction caused by excessive immune activation and cytokine release. The high morbidity and mortality rates are in part ...
Review Clinical advances in hematology & oncology : H&O. 2026 May;24(3):134-144. DOI: 2026
Highlights in multiple myeloma from the 2025 American Society of Hematology Annual Meeting [0.03%] 2025年美国血液学会年会多发性骨髓瘤研究亮点
Clinical advances in hematology & oncology : H&O. 2026 Mar-Apr;24(2):112-114. DOI: 2026
When will circulating tumor DNA be ready for prime time in lymphoma? [0.03%] 循环肿瘤DNA检测技术何时能应用于淋巴瘤的临床实践？
Mark Roschewski Mark Roschewski
Clinical advances in hematology & oncology : H&O. 2026 Mar-Apr;24(2):109-111. DOI: 2026
Optimal treatment for metastatic HER2+ breast cancer [0.03%] 转移性HER2阳性乳腺癌的优化治疗
Sara M Tolaney Sara M Tolaney
Clinical advances in hematology & oncology : H&O. 2026 Mar-Apr;24(2):106-108. DOI: 2026